PCRchitectur-based Prognostic Test

About Signatur Biosciences

Signatur Biosciences is a private, early-stage biotech company leveraging AI and molecular biology to revolutionize precision diagnostics. Its proprietary PCRchitectur platform transforms standard qPCR machines into tools capable of running complex, multi-gene expression tests, bypassing the need for expensive sequencers or central labs. Initially targeting breast cancer prognosis, the platform is designed to be versatile for many diseases, aiming to drastically improve access and turnaround times for molecular diagnostics. The company is led by a young, technically adept founder and supported by a scientific advisory board featuring a renowned academic and serial entrepreneur.

Therapeutic Areas

Other Breast Cancer Prognosis Drugs